{"product_id":"non-small-cell-lung-cancer-current-therapies-and-new-targeted-treatments-hardcover","title":"Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments - Hardcover","description":"\u003cp\u003eby \u003cb\u003eJunji Uchino\u003c\/b\u003e (Guest Editor)\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eConventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the \u003cem\u003eT790M\u003c\/em\u003e gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this \u003cem\u003eT790M\u003c\/em\u003e gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the \u003cem\u003eEML4-ALK\u003c\/em\u003e fusion gene (discovered in 2007), \u003cem\u003eROS1\u003c\/em\u003e gene, and \u003cem\u003eBRAF\u003c\/em\u003e gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents.\u003c\/p\u003e\u003cp\u003eAnother advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1\/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.\u003c\/p\u003e\u003cdiv\u003e\n\u003cstrong\u003eNumber of Pages:\u003c\/strong\u003e 258\u003c\/div\u003e\u003cdiv\u003e\n\u003cstrong\u003eDimensions:\u003c\/strong\u003e 0.81 x 9.61 x 6.69 IN\u003c\/div\u003e\u003cdiv\u003e\n\u003cstrong\u003ePublication Date:\u003c\/strong\u003e December 09, 2021\u003c\/div\u003e","brand":"Books by splitShops","offers":[{"title":"Default Title","offer_id":42546039685216,"sku":"9783036501307","price":83.52,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0598\/1922\/9280\/files\/ee0fdee7f5a86a09934c2759080d06c1.webp?v=1769344876","url":"https:\/\/bijoucc.myshopify.com\/products\/non-small-cell-lung-cancer-current-therapies-and-new-targeted-treatments-hardcover","provider":"CARIBBEAN CONNECT","version":"1.0","type":"link"}